balinatunfib   Click here for help

GtoPdb Ligand ID: 13583

Synonyms: SAR-441566 | SAR441566
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: SAR441566 is a small molecule that binds to TNF and disrupts signalling [2]. The chemical structure is claimed in UCB Biopharma/Sanofi patent WO2016050975A1 [1] and is a match for the INN balinatunfib (from INN proposed list 131, Aug. 2024). Mechanistically, balinatunfib/SAR441566 stabilises the TNF trimer in an inactive conformation [2]. It has been proposed as an orally available alternative to deliver the same therapeutic outcome as anti-TNF biologics in chronic autoimmune diseases.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 95.88
Molecular weight 502.52
XLogP 0.95
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1[C@@H]2C[C@H](C3=C(C=CC=C3C1=O)OC(F)F)N4C5=C(C=CC(=C5)C6=CN=C(C7(CCC7)N)N=C6)N=C24
Isomeric SMILES CN1[C@@H]2C[C@H](C3=C(C1=O)C=CC=C3OC(F)F)N4C2=NC5=C4C=C(C=C5)C6=CN=C(N=C6)C7(CCC7)N
InChI InChI=1S/C27H24F2N6O2/c1-34-20-11-19(22-16(24(34)36)4-2-5-21(22)37-26(28)29)35-18-10-14(6-7-17(18)33-23(20)35)15-12-31-25(32-13-15)27(30)8-3-9-27/h2,4-7,10,12-13,19-20,26H,3,8-9,11,30H2,1H3/t19-,20-/m1/s1
InChI Key UROFXMLQPAUCGV-WOJBJXKFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. De Haro Garcia T, Deligny M, Heer JP, Quincey JR, Xuan M, Zhu Z, Brookings DC, Calmiano MD, Evrard Y, Hutchings MC et al.. (2016)
Fused pentacyclic imidazole derivatives.
Patent number: WO2016050975A1. Assignee: Ucb Biopharma Sprl, Sanofi. Priority date: 02/10/2015. Publication date: 07/04/2016.
2. Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B et al.. (2022)
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Front Pharmacol, 13: 1037983. [PMID:36467083]